Using automated billing workflows with pre-submission claim scrubbing catches most of these systematically
The FLOW trial demonstrated that semaglutide significantly reduces the risk of major kidney endpoints in patients with type 2 diabetes and chronic kidney disease, irrespective of baseline cardiovascular status
Conclusion Currently, there is a large population of NAFLD/NASH patients who require long-term treatment, yet there is only one approved drug specifically for NASH, Rezdiffra (resmetirom), indicating that the clinical need is far from being fully met
They dont substitute good habits but can make them easier to maintain
Smith RP, Easson C, Lyle SM, et al
So its pretty problematic when theres a mold issue for the people that are in that 25%